Skip to main content
OpenTrials
Completed

NCT Number: NCT02974153

Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine

The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Migraine Disorders Brain Diseases Central Nervous System Diseases Headache Disorders Headache Disorders, Primary Nervous System Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Research Site, Brussels, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females between 18 and 65 years of age, inclusive, who were diagnosed with migraines at ≤ 50 years of age, and have a history of chronic migraine for ≥ 12 months before screening.
  • During the 28 day screening period, subjects must adequately complete the headache eDiary and must have headaches occurring on ≥ 15 to ≤ 26 days of which at least 8 must be migraine days.
  • Headache eDiary was completed on at least 24 of the 28 days prior to randomization.

Exclusion criteria

  • Confounding and clinically significant pain syndromes (e.g. fibromyalgia, chronic low back pain, complex regional pain syndrome).
  • Psychiatric conditions that are uncontrolled and/or untreated, including conditions that are not controlled for a minimum of 6 months prior to screening. Patients with a lifetime history of psychosis, mania, or dementia are excluded.
  • Any use of botulinum toxin for migraine or for any other medical/cosmetic reasons requiring injections within 4 months prior to screening and during the screening period.
  • History or diagnosis of complicated migraine (ICHD-III beta version, 20134), chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or sporadic and familial hemiplegic migraine.
  • Receipt of any monoclonal antibody treatment (within or outside a clinical trial) within 6 months before screening.
  • Previously dosed with ALD403 or any monoclonal antibody targeting the CGRP pathway.

Treatment and study plan

ALD403 (Eptinezumab)

Biological

Other names: Eptinezumab-jjmr, Vyepti

Placebo

Biological

Primary outcomes

  1. Change From Baseline in Monthly Migraine Days

    Time frame: Week 1-12

    Monthly migraine days are summarized in 28-day intervals, and averaged across Weeks 1-12

Secondary outcomes

  1. 75% Migraine Responder Rate

    Time frame: Week 1-12

    Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 12, as compared with baseline.

  2. 75% Migraine Responder Rate - 4 Week

    Time frame: Week 1-4

    Participants with an average reduction in migraine days of at least 75% over Weeks 1 to 4, as compared with baseline.

  3. 50% Migraine Responder Rate

    Time frame: Week 1-12

    Participants with an average reduction in migraine days of at least 50% over Weeks 1 to 12, as compared with baseline.

  4. Percentage of Participants With a Migraine on the Day After Dosing

    Time frame: Day 1

    The percentage of participants with a migraine on the day after dosing, where Day 0 is treatment Day and Day 1 is the day after dosing.

  5. Change in Monthly Acute Medication Days

    Time frame: Week 1-12

    An acute medication migraine day was a day with any triptan or ergotamine use as recorded in the eDiary.

  6. Change From Baseline of Headache Impact Test (HIT-6) Score

    Time frame: Baseline to Week 12

    The HIT-6 measures the impact of headache on the participant's functional health and well-being in 6 domains: pain; role functioning (ability to carry out usual activities); social functioning; energy or fatigue; cognition; and emotional distress assessed over the prior 12-week period. The total possible scores range from 36 (no impact) to 78 (worst impact).

  7. Change in Migraine Prevalence From Baseline to Week 4

    Time frame: Baseline to Week 4

    The avarage change in percentage of participants with a migraine on any given day during baseline and the equivalent avarage rate over Weeks 1-4.

  8. 75% Headache Responder Rate

    Time frame: Week 1-12

    Participants with an average reduction in headache days of at least 75% over Weeks 1 to 12, as compared with baseline.

  9. 50% Headache Responder Rate

    Time frame: Week 1-12

    Participants with an average reduction in headache days of at least 50% over Weeks 1 to 12, as compared with baseline.

  10. 100% Migraine Responder Rate

    Time frame: Week 1-12

    For each 4-week period the 100% response is determined, and the result for a participant is the average rate across Weeks 1-12. If a participant has one 4-week period out of 3 with 100% response, they are included as 33%.

  11. 100% Headache Responder Rate

    Time frame: Week 1-12

    For each 4-week period the 100% response is determined, and the result for a participant is the average rate across Weeks 1-12. If a participant has one 4-week period out of 3 with 100% response, they are included as 33%.

  12. Change From Baseline in Monthly Migraine Days (Weeks 13-24)

    Time frame: Week 13-24

    Monthly migraine days are summarized in 28-day intervals, and averaged across Weeks 13-24.

  13. Change From Baseline in Monthly Headache Days (Weeks 1-12)

    Time frame: Week 1-12

    Monthly headache days are summarized in 28-day intervals, and averaged across Weeks 1-12.

  14. Time to First Migraine After Dosing

    Time frame: 32 weeks

    The time to first migraine after dosing based upon the migraine data entered into the eDiary

  15. Change From Baseline to Week 12 in Percentage of Migraines With Use of Acute Medication

    Time frame: Week 1-12

    The percentage of migraines with acute medication usage. Participants with no migraine will be included with a rate of zero.

  16. Change From Baseline to Week 12 in Percentage of Headaches With Use of Acute Medication

    Time frame: Week 1-12

    The percentage of headaches with acute medication usage. Participants with no headaches will be included with a rate of zero.

  17. Percent Change in Frequency of Migraine Days - Week 1-12

    Time frame: Week 1-12

    The percent change in frequency of migraine days from Weeks 1-12 was calculated as the number of migraine days within 4-week intervals that were then averaged up to Week 12. The difference of this estimate from baseline was calculated as the change from baseline in the frequency of migraine days over Weeks 1-12.

  18. Percent Change in Frequency of Headache Days - Week 1-12

    Time frame: Week 1-12

    The percent change in frequency of headache days from Weeks 1-12 was calculated as the number of headache days within 4-week intervals that were then averaged up to Week 12. The difference of this estimate from baseline was calculated as the change from baseline in the frequency of headache days over Weeks 1-12.

  19. Change From Baseline in Percentage of Severe Migraines

    Time frame: Week 1-12

    The change from baseline in percentage of migraines that are classified as severe over Weeks 1-12.

  20. Change From Baseline in Percentage of Severe Headache

    Time frame: Week 1-12

    The change from baseline in percentage of headaches that are classified as severe over Weeks 1-12.

  21. Change From Baseline in Monthly Migraine Hours, Weeks 1-12

    Time frame: Week 1-12

    Migraine hours are the sum of migraines within 4 week intervals, and the average 4 week duration within 12 weeks.

  22. Change From Baseline in Monthly Headache Hours, Weeks 1-12

    Time frame: Week 1-12

    Headache hours are the sum of the duration of headaches within 4 week intervals, and the average 4 week duration within 12 week intervals.

  23. Duration of Migraine-Free Intervals

    Time frame: 32 weeks

    The number of participants with migraine-free intervals starting within the first 2 weeks of treatment. The longest migraine free interval for each participant is recorded.

  24. Change From Baseline of Short Form Health Survey (SF-36 v 2.0) Scale Scores

    Time frame: Baseline to Week 12

    The SF-36 is a health survey containing 36 questions consisting of eight scaled scores to measure quality of life over the past 4 weeks. All scales are on a range of 0 to 100, with 0 being the worst and 100 being the best. Scales are reported separately. Increases from baseline indicate improvement.

  25. Patient Global Impression of Change (PGIC) at Week 12

    Time frame: Week 12

    The PGIC includes a single question concerning the participant's impression of the change in their disease status since the start of the study. Seven responses are possible: Very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse.

  26. Health Related Quality of Life (EQ-5D-5L) at Week 12

    Time frame: Week 12

    The EQ-5D-5L is a descriptive system of health-related quality of life states consisting of 5 dimensions/questions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of five responses. The responses record five levels of severity (no problems/slight problems/moderate problems/severe problems/extreme problems) within a particular EQ-5D dimension.

Sponsors and collaborators

Lead sponsor

Alder Biopharmaceuticals, Inc.

Industry

Registry information

Official study title

A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine

Acronym: PROMISE 2

Important dates

Study start
2016
Primary completion
2017
Study completion
2018
First posted
Nov 28, 2016
Registry last updated
Jun 9, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.